CRISPR Gene Therapy CDMOs: The Manufacturing Backbone of Genome Editing Therapeutics
The approval of Casgevy (exagamglogene autotemcel) in 2023 marked a watershed moment for CRISPR-based gene therapies, but bringing these treatments from bench to bedside requires specialized manufacturing infrastructure that most biotech companies lack in-house. Contract Development and Manufacturing Organizations (CDMOs) with CRISPR expertise have become critical partners for sponsors navigating the path from IND-enabling studies to commercial supply.
Why Gene Therapy Manufacturing Is Different
CRISPR therapeutics demand manufacturing capabilities that go far beyond traditional biologics. Depending on the delivery modality, sponsors need partners with expertise in:
- Viral Vector Production (AAV, Lentivirus)
- For ex vivo gene editing approaches, CDMOs must produce clinical-grade viral vectors at scale — often requiring suspension bioreactors up to 2,000 L with validated purification processes and potency assays specific to gene-edited cell products.
- Lipid Nanoparticle (LNP) Formulation
- For in vivo CRISPR delivery — as pioneered by Intellia Therapeutics with NTLA-2001 — CDMOs need GMP-grade LNP encapsulation of guide RNA and Cas9 mRNA, with tight control over particle size, encapsulation efficiency, and endotoxin levels.
- Plasmid DNA Manufacturing
- High-quality plasmid DNA encoding guide RNAs and Cas proteins is foundational to both viral and non-viral approaches, requiring dedicated manufacturing suites with rigorous quality controls.
Market Landscape
According to Cell Trials Data, there are over 334 cell and gene therapy CMOs/CDMOs worldwide as of late 2025. However, the subset with validated CRISPR-specific capabilities — including guide RNA synthesis, ribonucleoprotein (RNP) complex assembly, and gene-edited cell product manufacturing — is considerably smaller. The global cell and gene therapy CDMO market was valued at approximately $8.2 billion in 2025 and is projected to grow at a 28% CAGR through 2034.
Key Selection Criteria for CRISPR CDMOs
| Criterion | What to Evaluate |
|---|---|
| Delivery Platform Expertise | Does the CDMO have validated processes for your specific modality (AAV, lentivirus, LNP, or RNP)? |
| Scale-up Track Record | Can they demonstrate successful tech transfer from process development through Phase III and commercial manufacturing? |
| Regulatory History | How many IND/CTA filings and BLA/MAA submissions has the CDMO supported? Any approved products? |
| Analytical Capabilities | In-house potency assays, genome editing efficiency analysis (NGS-based off-target detection), and release testing? |
| Supply Chain Security | Dual-sourced raw materials, qualified backup suites, and risk mitigation for critical reagents like Cas9 protein? |
Notable Industry Developments
The CDMO landscape has seen significant consolidation. Novo Holdings acquired Catalent for $16.5 billion in December 2024, creating one of the largest integrated biologics and gene therapy manufacturing platforms globally. Meanwhile, Andelyn Biosciences achieved a milestone by using its AAV Curator® platform to manufacture clinical-grade viral vector for the first-in-world FDA-authorized CRISPR/AAV-transduced CAR-NK cells. Ascend Gene & Cell Therapies raised $132.5 million specifically to launch as a CDMO specializing in AAV-based gene therapies.